Reducing Children's Distress Towards Flu Vaccinations

Sponsor
University of Calgary (Other)
Overall Status
Completed
CT.gov ID
NCT01529021
Collaborator
(none)
57
1
1
56

Study Details

Study Description

Brief Summary

Millions of children in North America receive an annual flu vaccination, many of whom are at risk of experiencing severe distress. Children frequently use technologically advanced devices such as computers and cell phones. Based on this familiarity, the investigators introduced another sophisticated device - a humanoid robot to- interact with children during their vaccination. The investigators hypothesized that these children would experience less distress than children who did not have this interaction.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    57 children (30 male; age, mean + SD: 6.87 + 1.34 years) were randomly assigned to a vaccination session with a nurse who used standard administration procedures, or with a robot who was programmed to use cognitive-behavioral strategies with them while a nurse administered the vaccination. Measures of distress were completed by children, parents, nurses, and researchers.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    57 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Study Start Date :
    Oct 1, 2011
    Actual Primary Completion Date :
    Nov 1, 2011
    Actual Study Completion Date :
    Nov 1, 2011

    Arms and Interventions

    Arm Intervention/Treatment
    humanoid robot distration

    The robot NAO, academic edition (Aldebaran Robotics) was used in this study. Some of its features include an on-board fully programmable computer CPU: x86 AMD Geode with 500 MHz, 256 MB SDRAM and 1 GB flash memory, WiFi (802.11g) and Ethernet, two cameras with up to 30 frames per second, two hands with self adaptive gripping abilities, force sensitive sensors on its arms and feet to perceive contact with objects, Light Emission Diodes in its eyes and body, four microphones to identify the source of sounds, and two loud speakers for communication where tone and voice pitch can be modified in real-time. It runs on a native Linux Operating system platform and can be programmed using a proprietary SDK called NaoQi, or in C, C++, Ruby and Urbi, which makes it compatible with other robot simulators such as Microsoft Robotics Developer Studio.

    control

    standard care procedures were used during the vaccination

    Outcome Measures

    Primary Outcome Measures

    1. Faces Pain Scale-Revised [5 mins before and immediate after vaccination]

      The Faces Pain Scale-Revised was administered to children and their parents while in the waiting room and after consent was signed. Once this questionnaire and consent were completed, the parent and child entered the vaccination room for the vaccination. As soon as the vaccination was completed, the Faces Pain Scale-Revised was re-administered.

    Secondary Outcome Measures

    1. Behavioral Approach-Avoidance Distress Scale [one week after vaccination was administered]

      The Behavioral Approach-Avoidance Distress Scale was used by researchers one week after the data collection phase was completed while reviewing the videos.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    5 Years to 9 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • ages 5-9 years,

    • boys and girls

    Exclusion Criteria:
    • children with pervasive developmental disability

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Alberta Children's Hospital Calgary Alberta Canada T3B 6A8

    Sponsors and Collaborators

    • University of Calgary

    Investigators

    • Principal Investigator: Tanya Beran, PhD, University of Calgary

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Tanya Beran, Associate Professor, University of Calgary
    ClinicalTrials.gov Identifier:
    NCT01529021
    Other Study ID Numbers:
    • E 23795
    First Posted:
    Feb 8, 2012
    Last Update Posted:
    Feb 8, 2012
    Last Verified:
    Feb 1, 2012
    Keywords provided by Tanya Beran, Associate Professor, University of Calgary

    Study Results

    No Results Posted as of Feb 8, 2012